You are here
Concluding Remarks and Future Perspectives (U-4)
T. Mok (Hong Kong)
Tony Mok looks to the future of ALK, showing that, whatever happened to EGFR, we are actually doing the same thing to the ALK-positive patient and concluding that we have to know the molecular data of each individual patient.
Considering the time, I will just move on to the last part of the presentation. I have tried to put everything close together, in perspective, and see what we can do in the future.
You have heard that we have the biomarkers here, like the ALK positive patient, crizotinib, and ceritinib may have a good CNS penetration.